Immune checkpoint inhibitors may play a role in the management of patients with certain gastroesophageal cancers. Join a leading oncology expert to review extended follow-up clinical trial data for an Immuno-Oncology (I-O)-based regimen used across certain metastatic gastroesophageal cancers. This is also an opportunity to ask questions to better understand the treatment landscape.
Key Takeaways:
– Get up to date on the latest clinical trial data for an (I-O)-based regimen in certain metastatic gastroesophageal cancers
– Understand how to incorporate I-O therapy into your treatment plan for appropriate patients with certain metastatic gastroesophageal cancers, regardless of their tumor location, histology, or PD-L1 status
